The Phase III clinical trial of GPN00833, a hormone nano-suspension eye drops developed by Yuanda Pharmaceuticals for anti-inflammatory and analgesic purposes, has successfully enrolled its first patient for treatment.

Wisdom Finance APP News: Yuanda Pharmaceutical announced that the Phase III clinical trial of GPN00833, a nano-suspension eye drop for anti-inflammatory and analgesic purposes, has recently completed the first patient dosing. This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase III clinical trial, aiming to evaluate the efficacy and safety of GPN00833 in treating inflammation and pain after cataract surgery in the Chinese population. It is another important research and development progress of the group in the field of ophthalmic disease treatment. It is reported that GPN00833 is a nano-suspension eye drop of anti-inflammatory and analgesic hormones. Its main active ingredient, chlorobutanol propionate, is a potent glucocorticoid with highly effective local anti-inflammatory activity and strong capillary constriction effect. At the same time, its unique nano-formulation process effectively solves the low water solubility of hormone products, resulting in low bioavailability and safety risks. This product has successfully achieved clinical endpoints in overseas Phase II clinical trials and two Phase III clinical trials. According to clinical results, GPN00833 has shown significant efficacy in postoperative anti-inflammatory and analgesic treatment in ophthalmology, with good safety. Currently, the product has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of this year.